BeOne Medicines (NASDAQ:ONC – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare BeOne Medicines to similar businesses based on the strength of its dividends, risk, valuation, profitability, earnings, institutional ownership and analyst recommendations.
Institutional and Insider Ownership
48.5% of BeOne Medicines shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current ratings and target prices for BeOne Medicines and its competitors, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BeOne Medicines | 0 | 1 | 16 | 1 | 3.00 |
| BeOne Medicines Competitors | 7845 | 13798 | 25820 | 1039 | 2.41 |
BeOne Medicines presently has a consensus price target of $440.56, suggesting a potential upside of 6.85%. As a group, “Pharmaceuticals” companies have a potential upside of 24.87%. Given BeOne Medicines’ competitors higher possible upside, analysts plainly believe BeOne Medicines has less favorable growth aspects than its competitors.
Earnings & Valuation
This table compares BeOne Medicines and its competitors top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| BeOne Medicines | $6.61 billion | $286.93 million | 52.39 |
| BeOne Medicines Competitors | $18.73 billion | $3.24 billion | 558.96 |
BeOne Medicines’ competitors have higher revenue and earnings than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares BeOne Medicines and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BeOne Medicines | 13.86% | 19.04% | 10.70% |
| BeOne Medicines Competitors | -2,398.26% | -203.62% | -15.08% |
Risk & Volatility
BeOne Medicines has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Comparatively, BeOne Medicines’ competitors have a beta of -0.04, indicating that their average stock price is 104% less volatile than the S&P 500.
Summary
BeOne Medicines beats its competitors on 8 of the 13 factors compared.
BeOne Medicines Company Profile
BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia. Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.
Receive News & Ratings for BeOne Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeOne Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
